series-c-plus
Stage
1
Investors
About
Medincell develops long-acting injectable drug-delivery technologies (BEPO®) and therapeutic products, partnering with pharma companies to commercialize treatments such as UZEDY (risperidone) and investigational olanzapine and celecoxib formulations.
Explore Medincell's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.